春秋航空(601021.SH):2019年員工持股計劃完成股票購買 累計買入73.6萬股
格隆匯12月6日丨春秋航空(601021.SH)公佈,截止本公告日,公司2019年員工持股計劃“興證資管鑫眾春秋航空2號員工持股單一資產管理計劃”已通過大宗交易方式累計買入公司股票73.6萬股,成交總金額2944萬元,佔公司總股本比例為0.08%,成交均價為人民幣40.00元/股。
至此,公司2019年員工持股計劃已完成股票購買,上述購買的股票將按照規定予以鎖定,鎖定期自本公告披露之日起12個月,從2019年12月7日起到2020年12月6日止。鎖定期結束後,將按《春秋航空股份有限公司2019年員工持股計劃》分批解鎖。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.